Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
Researchers have established that two simple tests can determine whether a person meets guidelines to receive antiviral treatment.
The observational study showed delays to diagnosis reduced the chances of identifying pathogens and generally led to poorer outcomes.
At the recent CVS, the two large health systems described introducing Cepheid platforms for flu testing across rural and satellite locations.
The workflow — which involves two immunoassays instead of the standard immunoassay followed by a Western blot — was tested using the agency's Lyme Serum Repository.
The firm expects to build out a menu for the reader, which will automate results reporting for colorimetric- and fluorescence-based tests.
The system will perform 200 multiplexed pathogen ID tests or 40 AST tests in one eight-hour shift on a random access, fully automated benchtop instrument.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.
The system will enable testing direct from a tube of blood using peptide nucleic acids-based methods to improve specificity.
The firm offers a high-throughput, automated and a low-throughput, manual solution and now plans to address mid-range needs with two new instruments.